Demoule, Alexandre
Baptiste, Amandine
Thille, Arnaud W.
Similowski, Thomas
Ragot, Stephanie
Prat, Gwénael
Mercat, Alain
Girault, Christophe
Carteaux, Guillaume
Boulain, Thierry
Perbet, Sébastien
Decavèle, Maxens
Belin, Lisa
Frat, Jean-Pierre
,
Clinical trials referenced in this document:
Documents that mention this clinical trial
Dyspnea is severe and associated with a higher intubation rate in de novo acute hypoxemic respiratory failure
https://doi.org/10.1186/s13054-024-04903-5
Funding for this research was provided by:
This work was supported by a grant from the French Ministry of Health
Article History
Received: 16 January 2024
Accepted: 5 April 2024
First Online: 23 May 2024
Declarations
:
: The original parent trial was approved by ethics committees at Centre Hospitalier Universitaire de Poitiers for French study sites (n. 10.11.28, 28 December 2010) and at Cliniques Universitaires Saint-Luc, Brussels for the site in Belgium (n. 10.07.12, 3 May 2011). Written informed consent was obtained from all the patients, their next of kin or another surrogate decision-maker as appropriate. According to French law, this post hoc analysis of the original study did not need additional ethics approval as no more data were collected for this analysis. Procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1975, as most recently amended.
: Not applicable.
: A Demoule reports grants from French Ministry of Health, Assistance publique—Hôpitaux de Paris, Lungpacer, Respinor, consulting fees from Respinor, Lungpacer, Lowenstein, Tribunal administrative de Cergy, Liberate Medical, Payment or honoraria for lectures, presentations from Fisher & Paykel, Baxter, Getinge, Astra, Agence Européenne Informatique, Mindray, support for attending meetings and/or travel from Lungpacer, outside the submitted work. A Baptiste has nothing to disclose. AW Thille reports payment or honoraria for lectures, presentations Fisher & Paykel, GE Healthcare, Philips, support for attending meetings and/or travel Fisher & Paykel, GE Healthcare, outside the submitted work. T Similowski reports grants from Lungpacer, consulting fees from ADEP Assistance, AstraZeneca France, Chiesi France, KPL consulting, Lungpacer Inc., Novartis France, TEVA France, Vitalaire, outside the submitted work. S Ragot has nothing to disclose G Prat has nothing to disclose A Mercat has nothing to disclose. C Girault reports payment or honoraria for lectures, presentations from Air Liquide Medical System, Medtronic, Dräger, support for attending meetings and/or travel from Fisher & Paykel, GE healthcare, Air Liquide Medical System, outside the submitted work. G Carteau reports payment or honoraria for lectures, presentations Air Liquide Medical System Medtronic Dräger, support for attending meetings and/or travel from Air Liquide Medical System outside the submitted work. T Boulain has nothing to disclose. S Perbet has nothing to disclose. L Belin has nothing to disclose. JP Frat reports non-financial support from Fisher and Paykel Healthcare (the firm provided material and equipment to all the participating centers), grant from the French Ministry of Heath, AADAIRC, French society of intensive care for the parent study, grants from the French Ministry of Heath, Fisher and Paykel Healthcare, consulting fees from SOS Oxygene, payment or honoraria for lectures from Fisher and Paykel Healthcare, support for attending meetings and/or travel from Fisher and Paykel Healthcare and SOS Oxygene, outside the submitted work.